Clinical risk factors of bevacizumab-related hypertension in patients with metastatic colorectal cancer: a retrospective study

IntroductionBevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, is widely used as a first-line treatment for metastatic colorectal cancer (mCRC), with hypertension being a common adverse effect. However, there is limited data on the predisposing factors contributing to bevacizumab-in...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhuoling Zheng (Author), Yihong Zhao (Author), Jingwen Xie (Author), Min Gao (Author), Yiting Wang (Author), Xiaoyan Li (Author)
Format: Book
Published: Frontiers Media S.A., 2024-10-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available